Omnicell, Inc. (NASDAQ:OMCL) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $1.22-$1.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.28. The company issued revenue guidance of $720-$740 million, compared to the consensus revenue estimate of $729.63 million.Omnicell also updated its Q3 guidance to $0.38-$0.45 EPS.
Shares of Omnicell, Inc. (NASDAQ OMCL) traded up 13.50% during midday trading on Friday, reaching $48.55. The company had a trading volume of 1,182,778 shares. The firm’s market capitalization is $1.80 billion. The company has a 50 day moving average price of $43.28 and a 200-day moving average price of $39.99. Omnicell, Inc. has a one year low of $30.35 and a one year high of $49.55.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting analysts’ consensus estimates of $0.02. The company had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. Omnicell’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 EPS. On average, analysts anticipate that Omnicell, Inc. will post $1.28 EPS for the current fiscal year.
A number of equities research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a buy rating and issued a $47.00 price target on shares of Omnicell in a report on Tuesday. Craig Hallum boosted their target price on shares of Omnicell from $46.00 to $52.00 and gave the company a buy rating in a report on Friday. Dougherty & Co boosted their target price on shares of Omnicell from $45.00 to $49.00 and gave the company a buy rating in a report on Friday. Zacks Investment Research raised shares of Omnicell from a sell rating to a hold rating in a report on Tuesday, July 4th. Finally, BidaskClub raised shares of Omnicell from a buy rating to a strong-buy rating in a report on Saturday, June 10th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $48.11.
In other Omnicell news, VP J Christopher Drew sold 10,625 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $40.97, for a total transaction of $435,306.25. Following the sale, the vice president now owns 152,057 shares of the company’s stock, valued at approximately $6,229,775.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Randall A. Lipps sold 37,500 shares of the company’s stock in a transaction on Friday, July 28th. The stock was sold at an average price of $46.00, for a total transaction of $1,725,000.00. Following the completion of the transaction, the chairman now directly owns 196,551 shares in the company, valued at approximately $9,041,346. The disclosure for this sale can be found here. Insiders have sold a total of 120,300 shares of company stock worth $5,199,801 in the last three months. Insiders own 3.77% of the company’s stock.
WARNING: This story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://stocknewstimes.com/2017/07/29/omnicell-inc-omcl-updates-fy17-earnings-guidance.html.
About Omnicell
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
